WO2019023651A3 - Modulateurs du récepteur des androgènes à petite molécule - Google Patents

Modulateurs du récepteur des androgènes à petite molécule Download PDF

Info

Publication number
WO2019023651A3
WO2019023651A3 PCT/US2018/044204 US2018044204W WO2019023651A3 WO 2019023651 A3 WO2019023651 A3 WO 2019023651A3 US 2018044204 W US2018044204 W US 2018044204W WO 2019023651 A3 WO2019023651 A3 WO 2019023651A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen receptor
small molecule
molecule modulators
compounds
useful
Prior art date
Application number
PCT/US2018/044204
Other languages
English (en)
Other versions
WO2019023651A2 (fr
Inventor
David Freeman
Nicholas B. STRUNTZ
Shelby K. DOYLE
Andre RICHTERS
Angela N. Koehler
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to US16/198,553 priority Critical patent/US10961216B2/en
Publication of WO2019023651A2 publication Critical patent/WO2019023651A2/fr
Publication of WO2019023651A3 publication Critical patent/WO2019023651A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

La présente invention concerne des composés utiles pour moduler l'activité d'un récepteur d'androgène, ou un variant de celui-ci, et des compositions et des procédés associés. Les composés de l'invention sont utiles pour exercer un effet antagoniste du variant d'épissage de récepteur d'androgène AR-v7, et pour le traitement du cancer de la prostate résistant à la castration.
PCT/US2018/044204 2017-07-28 2018-07-27 Modulateurs du récepteur des androgènes à petite molécule WO2019023651A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/198,553 US10961216B2 (en) 2017-07-28 2018-11-21 Small molecule modulators of the androgen receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538471P 2017-07-28 2017-07-28
US62/538,471 2017-07-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/198,553 Continuation US10961216B2 (en) 2017-07-28 2018-11-21 Small molecule modulators of the androgen receptor

Publications (2)

Publication Number Publication Date
WO2019023651A2 WO2019023651A2 (fr) 2019-01-31
WO2019023651A3 true WO2019023651A3 (fr) 2019-03-28

Family

ID=63209673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/044204 WO2019023651A2 (fr) 2017-07-28 2018-07-27 Modulateurs du récepteur des androgènes à petite molécule

Country Status (2)

Country Link
US (1) US10961216B2 (fr)
WO (1) WO2019023651A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141458A1 (fr) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Dérivés d'éther de bisphénol et leurs procédés d'utilisation
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
GB201914296D0 (en) * 2019-10-03 2019-11-20 Univ Oxford Innovation Ltd Treatment
CN115427028A (zh) * 2020-02-25 2022-12-02 田纳西大学研究基金会 选择性雄激素受体共价拮抗剂(sarca)及其使用方法
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途
US20220380378A1 (en) * 2021-04-22 2022-12-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical preparations that modulate IKZF2

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1329454A1 (fr) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Composes de thienopyrimidine et leurs sels et procede de preparation
WO2005042537A1 (fr) * 2003-10-22 2005-05-12 Bristol-Myers Squibb Company Composes bicycliques a substitution phenyl-aniline utilises comme inhibiteur de la kinase
US20060167053A1 (en) * 2003-02-26 2006-07-27 Tomoharu Iino Heteroarylcarbamoylbenzene derivative
WO2006124874A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
WO2011104337A1 (fr) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thiénopyrimidines contenant un groupe hétérocycloalkyle pour des compositions pharmaceutiques
US8053447B2 (en) * 2006-04-07 2011-11-08 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2013116491A1 (fr) * 2012-02-01 2013-08-08 Rigel Pharmaceuticals, Inc. Composés de carboxamide, de sulfonamide et d'amine et procédés pour utiliser ceux-ci
WO2017041040A1 (fr) * 2015-09-04 2017-03-09 City Of Hope Antagonistes du récepteur des androgènes
US20170095446A1 (en) * 2015-04-21 2017-04-06 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20170152260A1 (en) * 2013-01-15 2017-06-01 Board Of Regents, The University Of Texas System Stat3 inhibitor
WO2017165908A1 (fr) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Procédé d'inhibition d'états associés à un régime riche en matières grasses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
CN101384757A (zh) 2006-01-03 2009-03-11 哈佛大学校长及研究员协会 小分子印渍
WO2011044327A1 (fr) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Composés de phénylcarbamoyl alkylamino arènes substitués et composés de n,n'-bis-arylurée
ES2555393T3 (es) * 2009-12-18 2015-12-30 Glaxosmithkline Intellectual Property Limited Nuevos compuestos
CA2791114A1 (fr) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thienopyrimidines contenant un groupe alkyle substitue pour des compositions pharmaceutiques
CN102858782A (zh) * 2010-02-26 2013-01-02 贝林格尔.英格海姆国际有限公司 用于药物组合物的具有Mnk1/Mnk2 抑制活性的4-[环烷基氧基(杂)芳基氨基]噻吩并[2,3-d]嘧啶
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于***性疾病的生物标记物
CA2844640A1 (fr) 2013-12-06 2015-06-06 The University Of British Columbia Procede de traitement du cancer de la prostate resistant a la castration
CA2939048A1 (fr) 2014-02-14 2015-08-20 The University Of British Columbia Composes ciblant le domaine de liaison a l'adn (dbd) du recepteur des androgenes humain servant d'agents therapeutiques et procedes pour leur utilisation
WO2015150921A2 (fr) 2014-04-03 2015-10-08 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Procédés de traitement du cancer de la prostate
KR20160138136A (ko) * 2014-04-15 2016-12-02 연세대학교 산학협력단 티에노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 백혈병 치료 및 예방용 약학 조성물
WO2016049774A1 (fr) 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urée et composés à base de bis-urée et analogues de ceux-ci utiles dans le traitement de maladies ou trouble à médiation par récepteur des androgènes
GB201421933D0 (en) 2014-12-10 2015-01-21 Singapore Volition Pte Ltd Method for a detection of hormone sensitive diease progression
EP3268087A4 (fr) 2015-03-12 2018-08-29 The Regents of the University of California Méthodes de traitement du cancer par des inhibiteurs de ror gamma
US10173978B2 (en) 2015-08-05 2019-01-08 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
WO2017066697A1 (fr) 2015-10-14 2017-04-20 Dou Qingping Traitements et diagnostics de cancers
US20190060296A1 (en) 2017-07-28 2019-02-28 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1329454A1 (fr) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Composes de thienopyrimidine et leurs sels et procede de preparation
US20060167053A1 (en) * 2003-02-26 2006-07-27 Tomoharu Iino Heteroarylcarbamoylbenzene derivative
WO2005042537A1 (fr) * 2003-10-22 2005-05-12 Bristol-Myers Squibb Company Composes bicycliques a substitution phenyl-aniline utilises comme inhibiteur de la kinase
WO2006124874A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
US8053447B2 (en) * 2006-04-07 2011-11-08 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2011104337A1 (fr) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thiénopyrimidines contenant un groupe hétérocycloalkyle pour des compositions pharmaceutiques
WO2013116491A1 (fr) * 2012-02-01 2013-08-08 Rigel Pharmaceuticals, Inc. Composés de carboxamide, de sulfonamide et d'amine et procédés pour utiliser ceux-ci
US20170152260A1 (en) * 2013-01-15 2017-06-01 Board Of Regents, The University Of Texas System Stat3 inhibitor
US20170095446A1 (en) * 2015-04-21 2017-04-06 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2017041040A1 (fr) * 2015-09-04 2017-03-09 City Of Hope Antagonistes du récepteur des androgènes
WO2017165908A1 (fr) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Procédé d'inhibition d'états associés à un régime riche en matières grasses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUSH DALAL ET AL: "Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 38, 19 September 2014 (2014-09-19), US, pages 26417 - 26429, XP055357599, ISSN: 0021-9258, DOI: 10.1074/jbc.M114.553818 *
MENDEL ET AL: "Anthranilamide inhibitors of factor Xa", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 17, no. 17, 4 August 2007 (2007-08-04), pages 4832 - 4836, XP022184918, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.06.051 *

Also Published As

Publication number Publication date
WO2019023651A2 (fr) 2019-01-31
US10961216B2 (en) 2021-03-30
US20190202800A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
WO2019023651A3 (fr) Modulateurs du récepteur des androgènes à petite molécule
AU2019362061A8 (en) Androgen receptor modulators and methods for their use
WO2018195439A3 (fr) Modulateurs de k-ras
MX2020005748A (es) Metodos y composiciones para modular el empalme.
PH12020550523A1 (en) Modulators of the integrated stress pathway
AU2017261336A1 (en) Modulators of the integrated stress pathway
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
AU2017260367A1 (en) Modulators of the integrated stress pathway
AU2017260374A1 (en) Modulators of the integrated stress pathway
PH12020550524A1 (en) Modulators of the integrated stress pathway
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
BR112018073781A2 (pt) uso de agentes de modulação de glutamato com imunoterapias para o tratamento de câncer
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
PH12021550786A1 (en) Prodrug modulators of the integrated stress pathway
WO2016100619A3 (fr) Traitement et diagnostic du cancer
EP4112611A3 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
EP4223317A3 (fr) Modulation de l'activité du complément
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
WO2019023654A3 (fr) Découverte de petites molécules ciblant le récepteur des androgènes et leurs utilisations
AU2016276316B2 (en) Nuclear receptor modulators
NZ761519A (en) Nlrp3 modulators
MX2020011344A (es) Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18755607

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18755607

Country of ref document: EP

Kind code of ref document: A2